Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176890 | 0.86 | BCAT2 (0.44) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3593547 | 0.82 | KDM4E (0.44) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL4221247 | 0.81 | KDM4E (0.42) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL1928794 | 0.81 | KDM4E (0.42) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL3727463 | 0.79 | ADRA1D (0.45) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL4553805 | 0.79 | KDM4E (0.44) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL8930563 | 0.78 | KDM4E (0.47) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL630666 | 0.78 | KDM4E (0.47) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL83923 | 0.77 | KDM4E (0.50) | BCAT2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL630127 | 0.77 | KDM4E (0.45) | BCAT2KDM4EALDH1A1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287493-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS | BAYER SCHERING PHARMA AG (DE) | 2008-11-20 | — | — | US | claimed |
| WO-2008131972-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-GAMMA-AMINOALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | claimed |
| EP-1985612-A1 | Arymethylen substituted N-Acyl-gamma-aminoalcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | claimed |
| US-20080287493-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS | BAYER SCHERING PHARMA AG (DE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008131972-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-GAMMA-AMINOALCOHOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1985612-A1 | Arymethylen substituted N-Acyl-gamma-aminoalcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287493-A1 | ARYLMETHYLEN SUBSTITUTED N-ACYL-Y-AMINOALCOHOLS | FSHR, CYP19A1, GNRHR | BCAT2 174/4885KDM4E 190/4885ALDH1A1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.